Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype.
- Trial name
- VOLFI (NCT01328171)
- Testing
- FOLFOXIRI + Panitumumab, FOLFOXIRI
- Where
- 19 sites in Germany
- Volunteers
- 93 people
- Sponsor
- AIO-Studien-gGmbH
Colorectal Cancer, Colorectal Adenocarcinoma
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
In this study, the investigational drug, temsirolimus, will be combined with cetuximab, a biologic agent used in the treatment of colorectal cancer.
- Trial name
- NCT00593060
- Testing
- Temsirolimus, Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jeffrey W. Clark, MD
Chronic Limb-Threatening Ischemia, Colorectal Carcinoma
Comparison of Outcomes of Patients With Stage IV Chronic Limb-threatening Ischemia and Colorectal Cancer
Colorectal cancer (CRC) and chronic limb-threatening ischemia (CLTI) are relatively frequent and potentially fatal diseases. However, studies that are comparing clinical outcomes between CRC and CLTI patients in more advanced…
- Conditions
- Chronic Limb-Threatening Ischemia, Colorectal Carcinoma, Colorectal Carcinoma Metastatic in the Liver
- Trial name
- NCT05116696
- Testing
- For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery
- Where
- Serbia
- Volunteers
- 836 people
- Sponsor
- Clinical Centre of Serbia
Colorectal Cancer, Resistance
Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)
Cancer-derived inflammation attenuates the efficacy of adjuvant chemotherapy (CT) in postoperative or metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer, Resistance, Bevacizimab, Inflamation
- Trial name
- NCT07241403
- Where
- China
- Volunteers
- 698 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Unresectable Metastatic Colorectal Cancer
OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
- Trial name
- VELVET (NCT01802684)
- Testing
- aflibercept
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Colorectal Cancer
European Physician Survey of EGFR Inhibitor Prescribing Patterns
To ensure the appropriate administration of Vectibix for the treatment of mCRC with wild-type KRAS in real-world practice, it is important to understand the awareness of practicing oncologists regarding the correct indication and…
- Trial name
- NCT01652833
- Testing
- Physician Survey
- Volunteers
- 453 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver.
- Trial name
- NCT00803647
- Testing
- cetuximab, 5-FU, oxaliplatin
- Where
- 23 sites in United States
- Volunteers
- 20 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer, RAS and BRAF Wild-type
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with Metastatic Colorectal Carcinoma(CRC) as 1st Therapy.
- Conditions
- Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms, Intestinal Neoplasms
- Trial name
- ALTER-C-002 (NCT04080843)
- Testing
- Anlotinib Hydrochloride, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to…
- Trial name
- BEV-ONCO2012 (NCT01858649)
- Testing
- Metastases resection, Bevacizumab, 5 FU
- Where
- 11 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cancer, Cancer Metastatic
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors.
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT05131815
- Testing
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Metastatic Colorectal Cancer (MCRC)
Phase I/II Combination With Irinotecan- Erbitux
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median…
- Trial name
- NCT00594984
- Testing
- Cetuximab, Irinotecan, Brivanib
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
- Trial name
- TERRA (NCT01955837)
- Testing
- TAS-102
- Where
- 4 sites in China, South Korea and 1 more
- Volunteers
- 406 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer, Recurrent Colorectal Cancer
Phase I/II Trial of Antagonism of HER in GI Cancer
Recruitment to phase I of the PANTHER trial is complete. Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
- Trial name
- PANTHER (NCT01862003)
- Testing
- AZD8931, Irinotecan, Folinic Acid
- Where
- 4 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University College, London
Metastatic Colorectal Cancer, Chemotherapy Effect
Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer
This is a single-arm, open-label, single-center prospective phase II study to evaluate the efficacy and safety of rechallenge chemotherapy in the third or later-line treatment in patients with advanced colorectal cancer.
- Trial name
- NCT03485027
- Testing
- the rechallenge regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fudan University
Colorectal Cancer
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in…
- Trial name
- CanStem303C (NCT02753127)
- Testing
- Napabucasin, Fluorouracil, Leucovorin
- Where
- 211 sites in United States, Australia and 14 more
- Volunteers
- 1,253 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
This phase II trial studies how well nivolumab and metformin work in treating patients with microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous treatment.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer
- Trial name
- NCT03800602
- Testing
- Metformin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Emory University
Rectum Cancer
A Lymph Node Metastasis Predictor (LN-MASTER) in Rectal Cancer
In this study, we aim to develop and validate an easy-to-use machine learning prediction model to preoperatively identify the lymph node metastasis status for rectal cancer patients by using these clinical data from three…
- Trial name
- NCT05493930
- Testing
- The hospital where the treatment is performed
- Volunteers
- 6,578 people
- Sponsor
- Peking Union Medical College
Colorectal Cancer
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
This observational study will evaluate the use of Avastin (bevacizumab) and conventional chemotherapy in patients >/= 70 years of age with previously untreated metastatic colorectal cancer.
- Trial name
- NCT01676922
- Where
- 33 sites in Belgium
- Volunteers
- 256 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
One of the treatments generally used to treat this disease is a chemotherapy called FOLFIRI. The purpose of this study is to improve the efficacy of the chemotherapy by adding a protein, similar to immunoglobulins, aflibercept…
- Trial name
- NCT02181556
- Testing
- FOLFIRI Protocol, Aflibercept Injection
- Where
- 8 sites in France
- Volunteers
- 41 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.